Author Login

Correspondence to Author: Ralf Hofheiewnz, Sylvie Lorenzedwn and Micehael K. Bohlmdeann, 

American University of Beirut.

Introduction: The United States of America (USA) licensed trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), about 25 years ago for the treatment of patients with metastatic HER2-positive breast cancer. Since then, patients with HER2-positive breast cancer have benefited greatly from HER2-targeted treatment in a number of ways: (i) double targeting with pertuzumab and trastuzumab has been introduced into both the metastatic and neoadjuvant treatment settings; (ii) HER2-targeted therapy has transitioned from the palliative to the adjuvant and then to the neoadjuvant treatment settings; (iii) Patients with metastatic illness are now being treated with tyrosine kinase inhibitors including lapatinib, tucatinib, and neratinib, sometimes in conjunction with trastuzumab. allowing HER2- directed treatment in multiple treatment lines; (iv) antibody– drug conjugates, specifically trastuzumab emtansine and trastuzumab deruxtecan

Citation:

Ralf Hofheiewnz. The Field Of Her-2-Positive Tumors Is Constantly Changing In The Study Of Cancer. Journal Of Cancer And Tumor Research 2025.